Physician profile
David Cao
NPI 1437758653
$5,889.69
in general payments reported to CMS, 2019-2025
33 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,020 · 2022: $1,773 · 2023: $1,655 · 2024: $1,057 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,096.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,344.64 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $679.11 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Medtronic, INC. | $373.70 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $349.71 | 2021-2024 | Omnipod |
| Novo Nordisk INC | $324.19 | 2021-2023 | Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.98 | 2021-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $254.28 | 2021-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $238.62 | 2022-2025 | |
| Amgen INC. | $232.55 | 2021-2025 | Evenity, Prolia, Tepezza |
| Horizon Therapeutics Plc | $186.77 | 2021-2023 | Tepezza |
| Ibsa Pharma INC. | $167.81 | 2021-2023 | Tirosint, Licart |
| Radius Health, INC. | $148.42 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $147.76 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $142.43 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $138.88 | 2022-2023 | Farxiga |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $138.53 | 2023 | Crysvita |
| Sanofi-Aventis U.S. LLC | $131.09 | 2022-2024 | |
| Madrigal Pharmaceuticals | $101.60 | 2024 | Resmetirom |
| Abbvie INC. | $89.73 | 2021-2024 | |
| Recordati_rare_diseases_inc. | $50.16 | 2021-2024 | Isturisa, Signifor Lar |
| Mannkind Corporation | $41.72 | 2022 | |
| Averitas Pharma INC. | $41.21 | 2025 | Qutenza |
| Corcept Therapeutics | $38.33 | 2024-2025 | Korlym |
| Pfizer INC. | $37.55 | 2024 | |
| Merck Sharp & Dohme LLC | $36.60 | 2021-2022 | |
| Lifescan, INC. | $34.67 | 2021-2022 | |
| Bigfoot Biomedical INC | $24.79 | 2022 | |
| Ionis Pharmaceuticals, INC. | $23.43 | 2025 | Tryngolza |
| Amryt Pharma Holdings LTD | $20.71 | 2022 | |
| Alvogen INC | $19.30 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.70 | 2021 | |
| Tolmar, INC. | $16.92 | 2024 | |
| Cequr Corporation | $16.80 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.